Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan for Vincristine-Induced Neuropathy in Lymphoma
NCT03688633Phase 2Terminated
- Sponsor
- CHU de Limoges
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of candesartan in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by CHU de Limoges. Primary endpoint: Total Neuropathy Score clinical version variation at 15 weeks. Started May 2019; status: terminated.
02
Drugs
candesartan
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03688633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688633.